All novo nordisk Articles

How a boom in weight loss drugs could fatten construction firms’ order backlogs
A new generation of diabetes and weight-loss drugs are sparking a boom in pharmaceutical factory construction projects
Novo Nordisk to spend $1.1bn to expand Brazilian plant
Danish drug company Novo Nordisk has announced plans to invest 6.4 billion reais (US$1.1 billion) to expand production at a manufacturing plant in Brazil.
Novo Nordisk to build US$1.2 billion drug production facility in Denmark
New rare diseases facility design to be modular
Ozempic drugmaker selects BE&K for US factory expansion
Premium Content
Ozempic maker has selected a US-based firm for its new factory
Weekly quiz: What type of facility is major drug company spending $4.1bn to build?
Premium Content
It’s the Construction Briefing weekly news quiz - how much attention have you been paying to events in the world of construction over the past seven days?
Drug-maker Novo Nordisk to spend $4.1bn on construction of US Wegovy facility
Premium Content
Danish drug-maker Novo Nordisk is to spend $4.1 billion to build a new US facility to fill injection pens for its popular weight-loss treatment Wegovy
Demand for weight-loss drugs spurs Novo Nordisk to invest €2.1bn in French production site
Premium Content
Danish drug company Novo Nordisk is to invest 16 billion Danish kroner (€2.1 billion) to expand its production facilities in Chartres, France amid high demand for its weight-loss drugs Ozempic and Wegovy.